A board-certified pediatric surgeon with nearly three decades of experience in the field, Mark Holterman, MD, currently serves as a professor at the University of Illinois College of Medicine. Committed to advancing medicine, Dr. Mark Holterman supports the efforts of the American Diabetes Association (ADA). Senior citizens in the United States a higher risk of developing type 2 diabetes, with more than 25 percent of those aged 60 and over living with the disease. That’s why the ADA recently came out in support of a major new initiative known as the Medicare Diabetes Prevention Program (MDPP). This program will serve as an awareness and intervention platform with the goal of reducing the rate of diagnosis by providing support to community providers who, in turn, will be better equipped to provide screening and other services to at-risk communities. The new program will not only help reduce the rate of type 2 diabetes in seniors but will also help deal with rising health care costs that come from treating the illness.
Working at the University of Illinois College of Medicine as a professor of surgery and pediatrics, Dr. Mark Holterman has an interest in the field of biotechnology. Mark Holterman, MD, serves on the board of several organizations, including the Alliance for the Advancement of Cellular Therapies (AACT).One of the leading organizations supporting a Registry of Cell Therapy, AACT believes that establishing a well-curated registry will help address many of the common criticisms about the use of cell therapy, such as concerns about incomplete patient data and the variable quality of stem cells. The proposed registry would also ensure that stem cells are used only for valid treatment strategies according to review board protocols. With a registry, researchers also could address concerns about unreliable data by identifying standardized metrics to apply at uniform points in time by objective observers. Finally, the registry would allow the Food and Drug Administration to audit every aspect of stem cell research data to evaluate safety and efficacy.
